Oxygenta Pharmaceutical share news, announcements and annual reports
BSE: 524636Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 30 Oct 2026. Previous close ₹47.86.
30 Oct: open ₹47.01, high ₹48.21, low ₹46.89
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹175 Cr2,423rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Net worth zero or below
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business.
- Net worth zero or below
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −15.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- Net worth zero or below
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 2,027
Oxygenta Pharmaceutical share news and announcements
489 announcements, routine notices left out, newest first. Page 8 of 10.
May 2019
Apr 2019
Mar 2019
Feb 2019
4 Feb · Board meeting
Meeting on 14 Feb 2019: quarterly results
Jan 2019
21 Jan · Shareholding for the Period Ended December 31, 2018
Shareholding Pattern for the Period Ended December 31, 2018. For more details, kindly Click ....19 Jan · Statement Of Investor Complaints For The Quarter Ended December 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Dec 2018
Nov 2018
Oct 2018
30 Oct · Sub: Certificate Under Regulation 40(9) Of The SEBI (LODR) 2015, For The Half Year Ended 30Th September, 2018. Ref: Scrip Id: SSORGS, Scrip Code: 524636
30 Oct · Compliance Certificate For The Half Year Ended In The FY 2018-19 I.E. 30Th September, 2018. Ref: Scrip Id: SSORGS, Scrip Code: 524636
25 Oct · Shareholding for the Period Ended September 30, 2018
Shareholding Pattern for the Period Ended September 30, 2018. For more details, kindly Click ....20 Oct · Statement Of Investor Complaints For The Quarter Ended September 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 03 Oct · Results
Details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly ....
Sep 2018
29 Sep · Meeting
6 Sep · Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015
Aug 2018
Jul 2018
21 Jul · Shareholding for the Period Ended June 30, 2018
Shareholding Pattern for the Period Ended June 30, 2018. For more details, kindly Click ....10 Jul · Statement Of Investor Complaints For The Quarter Ended June 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Jun 2018
5 Jun · Compliance Certificate For The Half Year Ended In The FY 2017-18 I.E.31St March, 2018
5 Jun · Certificate Under Regulation 40(9) Of The SEBI (LODR) 2015, For The Half Year Ended 31St March, 2018.
May 2018
30 May · Shareholding for the Period Ended March 31, 2018
Shareholding Pattern for the Period Ended March 31, 2018. For more details, kindly Click ....
Apr 2018
5 Apr · Statement Of Investor Complaints For The Quarter Ended March 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Feb 2018
5 Feb · Compliance With Clause 29 Of The SEBI (LODR), 2015
Jan 2018
19 Jan · Shareholding for the Period Ended December 31, 2017
Shareholding Pattern for the Period Ended December 31, 2017. For more details, kindly Click ....12 Jan · Management
Nov 2017
14 Nov · Results
Oct 2017